Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03168438
Title NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

multiple myeloma

Therapies

NY-ESO-1-c259T

NY-ESO-1-c259T + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.